A targeted peritransplant antifungal strategy for the prevention of invasive fungal disease after lung transplantation: A sequential cohort analysis

Transplantation

Volumn 94, Issue 3, 2012, Pages 281-286

  Koo, Sophia ^a   Kubiak, David W ^a   Issa, Nicolas C ^a   Dietzek, Amanda ^a   Boukedes, Steve ^a   Camp, Phillip C ^a   Goldberg, Hilary J ^a   Baden, Lindsey R ^a   Fuhlbrigge, Anne L ^a   Marty, Francisco M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antifungal prophylaxis; Invasive aspergillosis; Invasive candidiasis; Invasive fungal disease; Lung transplantation

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FUNGUS CULTURE; FUNGUS GROWTH; HUMAN; INFECTION PREVENTION; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; SYSTEMIC MYCOSIS;

ADULT; AGED; AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; COHORT STUDIES; ECHINOCANDINS; FEMALE; HUMANS; LIPOPEPTIDES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MYCOSES; RISK; TIME FACTORS; TRIAZOLES;

EID: 84864712986     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318255f864     Document Type: Article

References (22)

1. Singh N, Husain S. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9(suppl 4): S180.
2. Husain S, Paterson DL, Studer S, et al. Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008.
3. Westney GE, Kesten S, De Hoyos A, et al. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915.
4. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417.
5. Alexander BD, Smith PB, Davis RD, et al. The (1,3){beta}-D-glucan test as an aid to early diagnosis of invasive fungal infections following lung transplantation. J Clin Microbiol 2010; 48: 4083.
6. Dummer JS, Lazariashvilli N, Barnes J, et al. A survey of anti-fungal management in lung transplantation. J Heart Lung Transplant 2004; 23: 1376.
7. Neoh CF, Snell GI, Kotsimbos T, et al. Antifungal prophylaxis in lung transplantationVA world-wide survey. Am J Transplant 2011; 11: 361.
8. Cadena J, Levine DJ, Angel LF, et al. Antifungal prophylaxis with voriconazole or itraconazole in lung transplant recipients: hepatotoxicity and effectiveness. Am J Transplant 2009; 9: 2085.
9. Minari A, Husni R, Avery RK, et al. The incidence of invasive aspergillosis among solid organ transplant recipients and implications for prophylaxis in lung transplants. Transpl Infect Dis 2002; 4: 195.
10. Kramer MR, Amital A, Fuks L, et al. Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Clin Transplant 2010; 25: E163.
11. Han K, Capitano B, Bies R, et al. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients. Antimicrob Agents Chemother 2010; 54: 4424.
12. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225.
13. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813.
14. Arthurs SK, Eid AJ, Deziel PJ, et al. The impact of invasive fungal diseases on survival after lung transplantation. Clin Transplant 2010; 24: 341.
15. Schaenman JM, Rosso F, Austin JM, et al. Trends in invasive disease due to Candida species following heart and lung transplantation. Transpl Infect Dis 2009; 11: 112.
16. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101.
17. Thabut G, Christie JD, Kremers WK, et al. Survival differences following lung transplantation among US transplant centers. JAMA 2010; 304: 53.
18. Koo S, Bryar JM, Page JH, et al. Diagnostic performance of the (1Y93)-beta-D-glucan assay for invasive fungal disease. Clin Infect Dis 2009; 49: 1650.
19. Vadnerkar A, Nguyen MH, Mitsani D, et al. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29: 1240.
20. Wermers RA, Cooper K, Razonable RR, et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 2011; 52: 604.
21. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152: 761.
22. Stewart S, Fishbein MC, Snell GI, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant 2007; 26: 1229.